Navigation Links
The race toward an interferon free world: The current field of Hepatitis C Virus treatment research, including recent financial deals
Date:4/26/2013

NEW YORK, April 26, 2013 /PRNewswire/ -- Citeline®, an Informa business unit, and the world's leading research authority on pharmaceutical clinical trials has just published an exclusive whitepaper examining the current progress towards a remarkable improvement in the medical treatment for HCV.

(Logo: http://photos.prnewswire.com/prnh/20120917/NE75453LOGO

With news of the impending breakthrough in HCV treatment, Citeline reviews the current landscape of clinical trials and drugs in this competitive space as well as the recent history of HCV-related financial deals.  In addition the whitepaper takes a look at the timing of current Phase III trials evaluating all oral regimens to determine how long Gilead may be the sole player in this space.  

Based on information in Citeline's clinical trial intelligence tool, Trialtrove®, 83% of the 200 planned and ongoing Phase I-III clinical trials for pipeline HCV drugs (excluding vaccines) are being conducted by 10 companies; these 10 companies, including Bristol-Myers Squibb, Gilead, Merck and AbbVie, among others, are the focus of this report. Gilead leads in the number of Phase II trials and is conducting over twice as many as the next most active Phase II sponsor, Bristol-Myers Squibb.

According to Doro Shin , MPH, Citeline's Senior Analyst, Infectious & Genitourinary Diseases, "Gilead's lead in direct acting antiviral (DAA) agents for the treatment of HCV could lead to a shorter, oral, and interferon free treatment of the disease, with a dramatic reduction in unwanted side effects. This is truly a new era in HCV treatment. "

Moreover, in reviewing deals over the last five years we discovered between March 2008 and March 2013, there were a total of 18 HCV specific industry partnerships. In both years partnerships comprised of research and discovery and commercialization agreements occurred most frequently; however, three partnerships in 2012 also included licensing agreements. The complete report provides details of these partnership and M&A details including deal values.

"DAAs are clearly dominating in the HCV treatment field as evidenced by the clinical trial landscape and recent financial dealings," remarks Ms. Shin. "With these DAAs, the race is on toward the first interferon free HCV treatment regimen, but the contenders have entered themselves into different events to ensure that they get the gold."

To read this exclusive whitepaper - The race toward an interferon free world: The current field of HCV treatment research, including recent financial deals go to www.citeline.com/resource-center/whitepapers               

About Citeline
Citeline, Inc., an Informa company. Citeline is the world's most comprehensive source of real-time R&D and commercial intelligence featuring an unmatched data collection of global clinical trials, clinical trial investigator profiles, drug development pipelines and commercial intelligence.

Contact for Further Information
Sean McIntosh
Director of Marketing
Citeline Inc.
52 Vanderbilt Ave
7th Floor
New York, NY 10017
212-520-2741
sean.mcintosh@citeline.com 
www.citeline.com 


'/>"/>
SOURCE Citeline
Copyright©2012 PR Newswire.
All rights reserved

Related medicine technology :

1. Selexis Lubris Partnership Advances Difficult-to-Express Protein Towards Clinic
2. ResearchMoz.US: Direct to Consumer (DTC) Advertising in Pharmaceuticals - Shift From Traditional Mass-Media Platforms Towards Personalization via Online and Social Media- Market Research Report
3. Direct to Consumer (DTC) Advertising in Pharmaceuticals - Shift from Traditional Mass-Media Platforms towards Personalization via Online and Social Media
4. Medical Marijuana Inc. and Canipa Holdings Drive Dixie X and CanChew Gum Toward EU Marketing Approval And Clinical Development
5. Inovio Pharmaceuticals Takes Major Stride Toward Universal Influenza Vaccine
6. Active Pharmaceutical Ingredients (API) Market in the Americas to 2017 - Shift Towards Generics and Biosimilars as South and Central America Emerges as a Key Growth Region
7. The Shift from Treatment to Prevention: A Drive towards Cutting Healthcare Costs
8. Emerging Growth Pharmaceutical Company Creates Gravitational Pull Towards Their Products
9. In Vitro Diagnostics Markets Grow at Double the Pace of Pharma Markets in Shift toward Globalization
10. Optimism of Cannabis Patients Creates More Demand for Phytiva Brand of Cannabinoid Solutions as Illinois and New Hampshire Take Key Legislative Steps Toward Legalization of Medical Cannabis
11. Novartis signs on to support Malaria No Mores Power of One campaign to stride towards a future without malaria
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/25/2016)... According to market research "Global ... Demand Forecast to 2022 - Industry Insights by Type ... by P&S Market Research, the global insulin delivery device ... it is expected to grow at a CAGR of ... segment is expected to witness the fastest growth at ...
(Date:5/25/2016)... , May 25, 2016 Digital Health ... to it by the US Patent and Trademark ... technology includes proprietary processes for electronic opt-­in and ... and wellness programs, HIPAA compliance and otherwise. ... "Our technology allows for ...
(Date:5/25/2016)... 2016 ReportsnReports.com adds "Chronic ... that provides an overview on therapeutic pipeline of ... stages, therapeutics assessment by drug target, mechanism of ... type, along with latest updates, and featured news ... involved in the therapeutic development for Chronic Cough ...
Breaking Medicine Technology:
(Date:5/26/2016)... ... May 26, 2016 , ... ... for the Foundation Fighting Blindness, Long Island Chapter on June 4, 2016, 1:30-3:30 ... , Dr. Maisel, founder of Retina Group of New York , is ...
(Date:5/26/2016)... ... , ... Memorial Day Weekend marks the unofficial start of summer and the ... make sure your family and vehicle are ready to hit the road this weekend. ... deaths and an additional 50,500 serious injuries from motor vehicle crashes during the three-day ...
(Date:5/26/2016)... (PRWEB) , ... May 26, 2016 , ... The ... to host a six-week smoking cessation class starting June 6 at their clinic in ... http://www.gnahec.org . , Additionally, the Lung Institute has created a free downloadable 4 ...
(Date:5/26/2016)... ... May 26, 2016 , ... American orthopedic ... medical officer of Blue Horizon International (BHI), Brian Mehling, M.D., spoke at an ... during May 5-6, 2016 in Chicago, IL, USA. Dr. Mehling’s presentation was focused ...
(Date:5/26/2016)... ... May 26, 2016 , ... Power Systems, a ... first PowerWave Instructor Certification Course in Stoughton, Massachusetts. The course was led by ... through the 8 hour interactive course to qualify participants as certified PowerWave trainers. ...
Breaking Medicine News(10 mins):